<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411033</url>
  </required_header>
  <id_info>
    <org_study_id>PPS1999</org_study_id>
    <nct_id>NCT01411033</nct_id>
  </id_info>
  <brief_title>Poznan Prospective Study of Type 1 Diabetic Patients</brief_title>
  <acronym>PoProStu</acronym>
  <official_title>Poznan Prospective Study of Type 1 Diabetic Patients Treated With Intensive Insulin Therapy From the Onset of the Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the development and progression of chronic
      complications (retinopathy, neuropathy, diabetic chronic renal disease, cardiovascular
      events) in patients with type 1 diabetes treated from the onset of the disease with
      recommended method of intensive insulin therapy. All patients attended a five-day structured
      training program during first hospitalization and re-education once year during the
      observation. After five years of observation and next - once a year chronic complications are
      assessed. The investigators would like to evaluate also the relationship of the management of
      the disease, knowledge about the treatment and diabetes, insulin resistance and inflammatory
      markers with development and progression of chronic complications.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 1994</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinopathy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetic chronic renal disease</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropathy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>stroke, heart infarct, death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic management of diabetes</measure>
    <time_frame>1 year</time_frame>
    <description>HbA1c, hypoglycaemic episodes, lipid profile, blood pressure, BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima media thickness</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Microangiopathy</condition>
  <condition>Macroangiopathy</condition>
  <condition>Insulin Treatment Overcorrection</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed diabetes mellitus type 1</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 Caucasian patients with newly diagnosed type 1 diabetes admitted to the Department of
        Internal Medicine and Diabetology, Poznan University of Medical Sciences in years
        1994-1999, treated from the onset of the disease with intensive insulintherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type 1 diabetes mellitus with features of complete insulin deficiency
             (serum C-peptide level &lt;0.05 ng/ml, acetonuria, blood gases disturbances such as: pH
             &lt;7.30, BE&lt; -6 mmol/l, HCO3 &lt;18 mmol/l)

          -  Age &lt; 35 years old

          -  Educational course in intensive insulin therapy started at the onset of the disease
             after treatment of ketoacidosis

          -  Written consent

        Exclusion Criteria:

          -  Uncertain type of diabetes mellitus

          -  Kidney failure (serum creatinine level &gt; 1.1 mg/dl)

          -  Liver dysfunction (AspAt &gt; 31 U/l, AlAt &gt; 34 U/l)

          -  Acute inflammatory process

          -  Other concomitant diseases (i.e. neoplasm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorota A Zozulinska-Ziolkiewicz, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences</affiliation>
  </overall_official>
  <results_reference>
    <citation>Wegner M, Piorunska-Stolzmann M, Araszkiewicz A, Zozulinska-Ziolkiewicz D, Naskret D, Uruska A, Wierusz-Wysocka B. Does oxidized LDL contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes? Clin Biochem. 2012 Dec;45(18):1620-3. doi: 10.1016/j.clinbiochem.2012.08.019. Epub 2012 Aug 29.</citation>
    <PMID>22960236</PMID>
  </results_reference>
  <results_reference>
    <citation>Wegner M, Pioruńska-Stolzmann M, Araszkiewicz A, Zozulińska-Ziółkiewicz D, Wierusz-Wysocka B. Evaluation of paraoxonase 1 arylesterase activity and lipid peroxide levels in patients with type 1 diabetes. Pol Arch Med Wewn. 2011 Dec;121(12):448-54.</citation>
    <PMID>22157813</PMID>
  </results_reference>
  <results_reference>
    <citation>Araszkiewicz A, Uruska A, Zozulinska-Ziolkiewicz D, Pilacinski S, Wierusz-Wysocka B. Factors related to insulin resistance in type 1 diabetic patients treated with intensive insulin therapy from the onset of the disease. Diabetes Res Clin Pract. 2010 Nov;90(2):e23-4. doi: 10.1016/j.diabres.2010.05.010. Epub 2010 Jun 11.</citation>
    <PMID>20541277</PMID>
  </results_reference>
  <results_reference>
    <citation>Wegner M, Araszkiewicz A, Zozulińska-Ziółkiewicz D, Wierusz-Wysocka B, Pioruńska-Mikołajczak A, Pioruńska-Stolzmann M. The relationship between concentrations of magnesium and oxidized low density lipoprotein and the activity of platelet activating factor acetylhydrolase in the serum of patients with type 1 diabetes. Magnes Res. 2010 Jun;23(2):97-104. doi: 10.1684/mrh.2010.0207. Epub 2010 May 27.</citation>
    <PMID>20507838</PMID>
  </results_reference>
  <results_reference>
    <citation>Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D, Uruski P, Wierusz-Wysocka B. Insulin resistance is associated with microangiopathy in type 1 diabetic patients treated with intensive insulin therapy from the onset of disease. Exp Clin Endocrinol Diabetes. 2010 Aug;118(8):478-84. doi: 10.1055/s-0030-1249635. Epub 2010 Apr 6.</citation>
    <PMID>20373280</PMID>
  </results_reference>
  <results_reference>
    <citation>Wegner M, Araszkiewicz A, Pioruńska-Mikołajczak A, Zozulińska-Ziółkiewicz D, Wierusz-Wysocka B, Pioruńska-Stolzmann M. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem. 2009 Nov;42(16-17):1621-7. doi: 10.1016/j.clinbiochem.2009.07.023. Epub 2009 Aug 3.</citation>
    <PMID>19651120</PMID>
  </results_reference>
  <results_reference>
    <citation>Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M, Wierusz-Wysocka B. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Res Clin Pract. 2008 Jul;81(1):61-7. doi: 10.1016/j.diabres.2008.02.009. Epub 2008 Apr 2.</citation>
    <PMID>18378034</PMID>
  </results_reference>
  <results_reference>
    <citation>Araszkiewicz A, Zozulińska D, Trepińska M, Wierusz-Wysocka B. [Is intensive functional insulin therapy the method of choice in newly diagnosed type-1 diabetes mellitus?]. Pol Merkur Lekarski. 2004 Nov;17(101):463-6. Polish.</citation>
    <PMID>15754632</PMID>
  </results_reference>
  <results_reference>
    <citation>Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D, Wegner M, Grzelka A, Wierusz-Wysocka B. Does serum cystatin C level reflect insulin resistance in patients with type 1 diabetes? Clin Biochem. 2014 Sep;47(13-14):1235-8. doi: 10.1016/j.clinbiochem.2014.06.014. Epub 2014 Jun 20.</citation>
    <PMID>24956263</PMID>
  </results_reference>
  <results_reference>
    <citation>Uruska A, Araszkiewicz A, Uruski P, Zozulinska-Ziolkiewicz D. Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy. Microvasc Res. 2014 Mar;92:79-84. doi: 10.1016/j.mvr.2014.01.002. Epub 2014 Jan 12.</citation>
    <PMID>24423616</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2011</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aleksandra Uruska</investigator_full_name>
    <investigator_title>Prof. Dorota Zozulinska -Ziolkiewicz</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

